Singapore markets closed

LLY Jul 2024 980.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
1.09000.0000 (0.00%)
As of 03:10PM EDT. Market open.
Full screen
Previous close1.0900
Open1.0900
Bid1.9900
Ask2.3300
Strike980.00
Expiry date2024-07-19
Day's range1.0900 - 1.0900
Contract rangeN/A
Volume1
Open interest33
  • Zacks

    Play These New ETFs to Tap Lucrative Weight Loss Drug Market

    Global obesity rates have nearly tripled since 1975, per WHO and Goldman Sachs. The growing usage of GLP-1 drugs in weight management now makes the industry a thriving one.

  • PR Newswire

    More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved clinical remission at one year, including patients with previous biologic failure

    In Eli Lilly and Company's (NYSE: LLY) pivotal Phase 3 VIVID-1 study, patients with moderately to severely active Crohn's disease, with or without previous biologic failure, achieved statistically significant and clinically meaningful improvements across multiple clinical and endoscopic endpoints at one year with mirikizumab compared to placebo. Data from this study – the first Phase 3 treat-through data reported for an IL23p19 antibody – will be presented at Digestive Disease Week® (DDW), held

  • Reuters

    Eli Lilly's diabetes drug tirzepatide gets approval in China

    SHANGHAI (Reuters) -Eli Lilly said on Tuesday its diabetes drug tirzepatide has received approval from Chinese regulators, setting up intensifying competition with its Danish rival Novo Nordisk in the key Asian market. Novo Nordisk's popular diabetes drug Ozempic won approval from China in 2021 and the company saw sales of the weekly injection in the greater China region that includes Hong Kong and Taiwan double to 4.8 billion Danish Krone ($698 million) last year. Eli Lilly did not say when sales would begin in China or how many doses would be supplied.